34 results on '"Arife Ulas"'
Search Results
2. Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival
- Author
-
Erdem Cubukcu, Ömer Fatih Ölmez, Nilufer Bulut, Tugba Kos, Mustafa Degirmenci, Nilufer Avci, and Arife Ulas
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Adjuvant chemotherapy ,Breast cancer ,Grade III ,HER2 ,Trastuzumab ,Receptor, ErbB-2 ,Epidemiology ,Antineoplastic Agents ,Breast Neoplasms ,Immunoenzyme Techniques ,Median follow-up ,Internal medicine ,medicine ,Humans ,Neoplasm Invasiveness ,Stage (cooking) ,skin and connective tissue diseases ,In Situ Hybridization, Fluorescence ,Aged ,Neoplasm Staging ,Retrospective Studies ,Cardiotoxicity ,Univariate analysis ,business.industry ,Proportional hazards model ,Carcinoma, Ductal, Breast ,Public Health, Environmental and Occupational Health ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,Carcinoma, Lobular ,Receptors, Estrogen ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,Female ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies ,medicine.drug - Abstract
PubMed ID: 25743846 Background: The aim of the present study was to evaluate clinicopathological characteristics of our early stage breast cancer patients who are epidermal growth factor receptor 2 (HER2) overexpressed/ amplified (HER2+), the efficacy of trastuzumab treatment and survival results. Materials and Methods: Patients with HER2- positive early stage breast cancer receiving adjuvant trastuzumab were investigated retrospectively. Clinicopathological features of 210 patients and treatment outcome were analysed. To evaluate survival rates, the Kaplan-Meier method was used. Univariate and multivariate analyses were conducted with the Cox regression model. Results: Mean age of the patients was 51.8, 71.9% being postmenopausal. Some 37.6% of patients were node negative, and 31% had T1 tumor size and 52.4% were positive for estrogen receptor. Of 210 patients, 89.5% completed planned 52 weeks adjuvant trastuzumab treatment. The median follow up was 27.5 months (6.0-86.0 ). Relapse free survival (RFS) was 68.0 months (95% CI: 62.1-74.0) and overall survival (OS) was 74.8 months (95% CI: 69.5-80.1). The 3 year OS for all patients was 92.0% and RFS was 79.6%. During follow up, relapse was detected at the rate of 14.3%. Trastuzumab associated cardiotoxicity was found at the rate of 3.3%. In univariate analyses, larger tumor size and grade III were significantly associated (p
- Published
- 2015
3. Lung Cancer in Women, a Different Disease: Survival Differences by Sex in Turkey
- Author
-
Saadet Tokluoglu, Mehmet Kos, Kamile Silay, Berna Öksüzoğlu, Sema Akinci, Necati Alkis, and Arife Ulas
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Turkey ,Epidemiology ,Anemia ,Comorbidity ,Adenocarcinoma ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Carcinoma ,Humans ,Stage (cooking) ,Lung cancer ,Survival rate ,Aged ,Neoplasm Staging ,Retrospective Studies ,Gynecology ,business.industry ,Non-small cell lung cancer ,Sex differences ,Survival ,Smoking ,Public Health, Environmental and Occupational Health ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,Oncology ,Carcinoma, Squamous Cell ,Carcinoma, Large Cell ,Female ,business ,Follow-Up Studies - Abstract
PubMed ID: 25684531 Purpose: In this study, we aimed to evaluate the effects of sex-based non-small cell lung cancer (NSCLC) varieties on survival rates. Materials and Methods: A retrospective study was performed in patients with NSCLC who were diagnosed by histological methods between the years 2000 and 2010. A chi-square test was used to compare variables. Overall survival (OS) was estimated by the Kaplan-Meier method. Results: Of the 844 patients, 117 (13.9%) were women and 727 (86.1%) were men. Adenocarcinoma was more common in women than in men (p10%, stage, LDH, albumin and treatment between women and men. Women younger than 65 years (17.0 vs 12.0 months; p=0.03), who had adenocarcinoma histology (15.0 vs 10.0 months; p=0.006) and who had a hemoglobin level ?12g/dL (18.0 vs 12.0 months; p=0.01) were found to have a better median OS rate than men. Median OS rates were found to be 13.0 months in females and 12.0 months in males (p=0.14). Among metastatic patients, the median OS was 11.0 months in females and 8.0 months in males (p=0.005). Among stage IIIB and stage IV patients who had first line platinum-based chemotherapy, the median OS was 17.0 months in women and 11.0 months in men (p=0.002). The response rate of chemotherapy was higher in women than in men (p=0.03). Conclusions: In our study, we found that survival duration is longer and chemotherapy response is better in women with NSCLC who do not have anemia or comorbidities and who are mostly non-smokers with adenocarcinomas. Further studies regarding the causes of these differences may provide clarity on this subject.
- Published
- 2015
4. The Myth of Not Disclosing the Diagnosis of Cancer: Does it Really Protect Elderly Patients from Depression?
- Author
-
Merve Canbaz, Imdat Dilek, Arife Ulas, Muhammed Bulent Akinci, Sema Akinci, Esin Ozturk, Bulent Yalcin, Yavuz S. Silay, and Kamile Silay
- Subjects
Male ,Health Knowledge, Attitudes, Practice ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Patients ,Turkey ,Epidemiology ,Cross-sectional study ,MEDLINE ,Disclosure ,Neoplasms ,Surveys and Questionnaires ,medicine ,Humans ,Psychiatry ,Depression (differential diagnoses) ,Aged ,Depressive Disorder ,Hematologic cancer ,business.industry ,Public Health, Environmental and Occupational Health ,Cancer ,Middle Aged ,medicine.disease ,Cross-Sectional Studies ,Mood ,Oncology ,Marital status ,Female ,Geriatric Depression Scale ,business ,Attitude to Health ,Follow-Up Studies - Abstract
Background: The disclosure of a diagnosis of cancer is complex, particularly in older patients. The aim of this study was to investigate the association between age and not knowing the diagnosis, and its impact on mood. Materials and Methods: The study included 70 patients with various types of solid and hematologic cancer in early stages, which were followed up in an outpatient oncology/hematology clinic in Turkey between January, 2014 and June, 2014. Initially the caregivers of patients were asked whether the patients knew their diagnosis or not. A questionnaire for the Geriatric Depression Scale was then administered to the patients. Patient age, gender, marital status and education level were noted and analyzed with respect to knowing the diagnosis and depression. Results: Of the 70 patients, 40% of them were female. The mean age was 68.2 ± 8.9. The rate of the patients who does not know their diagnosis was 37.1% (n=26). The overall depression rate with GDS was found 37.1% (n=26) among the participants. There was no association with knowing the diagnosis (p=0.208) although the association between not knowing the diagnosis and age was significant (p=0.01). Conclusions: In this study we revealed no association between not knowing the diagnosis and depression in elderly patients. Contrary to what some has thought, the patient is not protected from psychological distress by not being informed about the diagnosis. We believe this study and similar ones will help to discuss and further explore patient autonomy, the principle of respect to self-determination and end of life issues in different cultures.
- Published
- 2015
5. Effectiveness and safety of LMWH treatment in patients with cancer diagnosed with nonhigh-risk venous thromboembolism (VTE): Results of the Turkish observational study (TREBECA)
- Author
-
Erdem Cubukcu, Arife Ulas, Emin Tamer Elkiran, Mustafa Benekli, Mehmet Aliustaoglu, Alper Sevinc, Gamze Gokoz Dogu, Abdurrahman Isikdogan, Berna Oksuzoglu, Irfan Cicin, Faysal Dane, Mukremin Uysal, Ersin Ozaslan, Aziz Karaoglu, Murat Koçer, and Metin Ozkan
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Turkish ,Cancer ,medicine.disease ,language.human_language ,Oncology ,Internal medicine ,medicine ,language ,In patient ,Observational study ,business ,Venous thromboembolism - Abstract
e21656 Background: Venous thromboembolism (VTE) is one of the most important causes of death in cancer patients, with VTE risk being 4-7 times higher among these patients compared to normal population. TREBECA is an observational study on cancer outpatients with low risk VTE treated with LMWH. Methods: Patients were treated by medical oncologists in Turkey at 15 sites, where they were enrolled and followed-up for a period of 12 months. Each center used their own treatment protocol. Primary endpoints were efficacy and the time to a change inVTE status (dissolution of thrombosis). The doses of LMWHs have been calculated according to patients’ body weights based on the dosage scheme and administered subcutaneously once or twice daily. Results: Data for 250 patients who met the study inclusion criteria were examined and analyzed. Of the included patients; 239 patients (95.6%) completed their Day 15 visit, 176 (70.4%) completed their Month 3 visit, 130 (52.0%) completed their Month 6 visit, and 91 (36.4%) completed the entire study. The mean age of the patients was 60.2 ± 13.7, while 53.2% (n = 133) of the patients were women. Colorectal (21.2%), lung (16.8%) and breast (14.8%) cancers were the most common forms of cancer. One hundred thirty-three patients were treated with enoxaparin, 112 patients were treated with bemiparin and 5 patients were treated with tinzaparin. Bemiparin resulted thrombosis resolution in more patients than enoxaparin, during day 15, month 3 and month 6 visits (table 1; p < 0.05). Conclusions: The observation that bemiparin is more effective in resolution of thrombosis was noteworthy. Thrombosis could not be effectively treated within the first 15 days in a significant number of patients, but could effectively be treated in most patients by Month 3. We can conclude that a treatment of at least 3 months is appropriate for cancer patients, even among those who are at low risk for venous thromboembolism. [Table: see text]
- Published
- 2017
6. Risk Factors for Stage IV Breast Cancer at the Time of Presentation in Turkey
- Author
-
Hasan Ergenç, Ummugul Uyeturk, Ali Murat Tatli, Derya Kivrak Salim, Arife Ulas, Özlem Sönmez, Berna Oksuzoglu, Seyda Gunduz, Mehmet Fatih Özbay, Sebahat Gucuk, Nilufer Avci, Muhammed Bulent Akinci, Fatma Akdag, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Üyetürk, Ümmügül, and Akdağ, Fatma
- Subjects
Health Knowledge, Attitudes, Practice ,Cancer Research ,medicine.medical_specialty ,Alcohol Drinking ,Turkey ,Stage IV Breast Cancer ,Hormone Replacement Therapy ,Receptor, ErbB-2 ,Epidemiology ,Breast Neoplasms ,Education ,Breast cancer ,Risk Factors ,Internal medicine ,medicine ,Humans ,Genetic Predisposition to Disease ,Family history ,Neoplasm Staging ,Retrospective Studies ,Cause of death ,Gynecology ,Univariate analysis ,business.industry ,Carcinoma, Ductal, Breast ,Smoking ,Public Health, Environmental and Occupational Health ,Cancer ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Carcinoma, Lobular ,Early Diagnosis ,Receptors, Estrogen ,Oncology ,Menarche ,Female ,Neoplasm Grading ,Receptors, Progesterone ,Live birth ,business ,Contraceptives, Oral ,Follow-Up Studies ,Mammography - Abstract
WOS:000331528900069 PubMed: 24460317 Background: Breast cancer (BC) is the one of the most common cancers in women. It is also a leading cause of death. Unfortunately, some patients initially present with distant metastases and are diagnosed with stage IV disease that is nearly always, by then, incurable. This retrospective analysis investigated the risk factors for stage IV BC that may underlie such late presentation. Materials and Methods: In all, 916 patients with BC who visited the medical oncology polyclinic of eight different centres in Turkeybetween December 2011 and January 2013 were analysed. Results: A total of 115 patients (12.6%) presented with stage IV disease. In univariate analysis; to comparing these with patients at other stages, no statistical difference was found for median diagnosis age or age at menarche (p=0.611 and p=0.820), whereas age at menopause and age at first live birth were significant (p=0.018 and p=0.003). No difference was detected in terms of accompanying diseases, use of oral contraceptives and hormone replacement therapy, smoking, alcohol consumption and the rate of family history of BC between the patients (p=0.655, p=0.389, p=0.762, p=0.813, p=0.229, p=0.737). However, screening methods were employed less often, the rate of illiteracy was higher, and the rate of other cancers was higher in patients with stage IV BC (p=0.022, p=0.022, p=0.018). No statistical difference was observed between the patients in terms of tumour histopathology, and status of oestrogen receptor, progesterone receptor, or human epidermal growth factor-2 receptor (p=0.389, p=0.326, p=0.949, p=0.326). Grade 3 tumours were more frequent in patients with stage IV disease (p
- Published
- 2013
7. Inhalt Band 35, 2012
- Author
-
Burcak Yilmaz, Mustafa Benekli, Jobst C. von Einem, Vladimir Bumbasirevic, Shinya Katsuno, Alper Sevinc, Michael J. Flaig, Jens Stieler, Osamu Nishiyama, Hiroyuki Taniguchi, Rudolf M. Huber, Sven Bischoff, Stefan Kubicka, Daniel Müller, Dogan Uncu, Alejandra Fernández, Veli Berk, Tomoki Kimura, Naoki Takashima, Michael Hallek, L. Jakovic, Rubén Romero, Takumi Umemura, Xavier Andreu, Arife Ulas, Fritz von Weizsäcker, Joan C. Julia, Berna Oksuzoglu, Bulent Cetin, Ibrahim Turker, Bosko Andjelic, Lokman Koral, Masahiro Fukatsu, Naoto Nakamura, Jiang Wang, Oliver Nehls, Yasuhiro Kondoh, Hakan Harputluoglu, Cem Onal, Biljana Mihaljevic, Mehmet Ali Kaplan, Fazilet Kayaselçuk, Suleyman Buyukberber, Naohiro Watanabe, Karel Caca, Ugur Coskun, Santiago Mourelo, Tamer Colakoglu, Zhi-Qiang Li, Abdurrahman Isikdogan, Kensuke Kataoka, Cecilia Baena, Santiago Escriva de Romaní, Marianne Sinn, Cornelia Then, Miguel H. Bronchud, Cheng-Shi Xu, Dogan Koca, Hanno Riess, Maja Perunicic Jovanovic, Zhi-Hua Wen, Ali Fuat Yapar, Keiko Arakawa, Nastaran Mohammadi Ghahhari, Andrija Bogdanovic, Sergi Castillo, Cem Boruban, Xiao-Dong Huang, Uwe Pelzer, Mehdi Kadivar, Hamed M. Ghahhari, Faysal Dane, Serife Ulusan, Jesús Murillo, Jordi Esquius, Martin Reincke, and Ling-Ling Gong
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2012
8. Contents Vol. 35, 2012
- Author
-
Fritz von Weizsäcker, Mehdi Kadivar, Miguel H. Bronchud, Naoto Nakamura, Takumi Umemura, Masahiro Fukatsu, Martin Reincke, Ling-Ling Gong, Oliver Nehls, Dogan Uncu, Sven Bischoff, Stefan Kubicka, Bulent Cetin, Serife Ulusan, Biljana Mihaljevic, Nastaran Mohammadi Ghahhari, Andrija Bogdanovic, Arife Ulas, Alejandra Fernández, Marianne Sinn, Jiang Wang, Naoki Takashima, Mustafa Benekli, Karel Caca, Jobst C. von Einem, Sergi Castillo, Veli Berk, Tomoki Kimura, Faysal Dane, Ugur Coskun, Abdurrahman Isikdogan, Fazilet Kayaselçuk, Osamu Nishiyama, Rudolf M. Huber, Joan C. Julia, Shinya Katsuno, Cecilia Baena, Hakan Harputluoglu, Berna Oksuzoglu, Jesús Murillo, Burcak Yilmaz, Santiago Mourelo, Cornelia Then, Hanno Riess, Maja Perunicic Jovanovic, Zhi-Hua Wen, Suleyman Buyukberber, Ali Fuat Yapar, Keiko Arakawa, Bosko Andjelic, Jens Stieler, Hamed M. Ghahhari, Lokman Koral, Zhi-Qiang Li, Daniel Müller, Tamer Colakoglu, Hiroyuki Taniguchi, Rubén Romero, Kensuke Kataoka, Santiago Escriva de Romaní, Cem Boruban, Cem Onal, Jordi Esquius, Naohiro Watanabe, Xiao-Dong Huang, Michael Hallek, L. Jakovic, Ibrahim Turker, Yasuhiro Kondoh, Alper Sevinc, Michael J. Flaig, Cheng-Shi Xu, Dogan Koca, Vladimir Bumbasirevic, Mehmet Ali Kaplan, Xavier Andreu, and Uwe Pelzer
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2012
9. Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer
- Author
-
Sercan Aksoy, Mehmet Ali Nahit Sendur, Arife Ulas, Bulent Yalcin, Nuriye Özdemir, Nurullah Zengin, Didem Sener Dede, and Muhammed Bulent Akinci
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Bone Neoplasms ,Docetaxel ,Castration resistant ,Gonadotropin-Releasing Hormone ,Prostate cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Randomized Controlled Trials as Topic ,business.industry ,Prostatic Neoplasms ,General Medicine ,medicine.disease ,Hormone-sensitive ,Clinical Trials, Phase III as Topic ,Hormonal therapy ,Taxoids ,business ,medicine.drug - Published
- 2015
10. Hospitalization risk according to geriatric assessment and laboratory parameters in elderly hematologic cancer patients
- Author
-
Esin Ozturk, Sema Akinci, Arife Ulas, Merve Canbaz, Bulent Yalcin, Yavuz S. Silay, Muhammed Bulent Akinci, Imdat Dilek, Kamile Silay, and Tekin Guney
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Activities of daily living ,Epidemiology ,Cross-sectional study ,Population ,Timed Up and Go test ,Risk Factors ,Internal medicine ,Activities of Daily Living ,medicine ,Outpatient clinic ,Humans ,education ,Geriatric Assessment ,Aged ,Geriatrics ,education.field_of_study ,Mini–Mental State Examination ,medicine.diagnostic_test ,business.industry ,Medical record ,Public Health, Environmental and Occupational Health ,Clinical Laboratory Services ,Prognosis ,Hospitalization ,Cross-Sectional Studies ,Oncology ,Hematologic Neoplasms ,Physical therapy ,Female ,business ,human activities ,Biomarkers ,Follow-Up Studies - Abstract
Background: Utilizing geriatric screening tools for the identification of vulnerable older patients with cancer is important. The aim of this study is to evaluate the hospitalization risk of elderly hematologic cancer patients based on geriatric assessment and laboratory parameters. Materials and Methods: In this cross sectional study 61 patients with hematologic malignancies, age 65 years and older, were assessed at a hematology outpatient clinic. Standard geriatric screening tests; activities of daily living (ADL), instrumental activities of daily living (IADL), Mini Nutritional Assessment (MNA), Mini Mental State Examination (MMSE), timed up and go test (TUG), geriatrics depression scale (GDS) were administered. Demographic and medical data were obtained from patient medical records. The number of hospitalizations in the following six months was then recorded to allow analysis of associations with geriatric assessment tools and laboratory parameters. Results: The median age of the patients, 37 being males, was 66 years. Positive TUG test and declined ADL was found as significant risk factors for hospitalization (p=0.028 and p=0.015 respectively). Correlations of hospitalization with thrombocytopenia, vitamin B12 and folic acid deficiency were statistically significant (p=0.004, p=0.011 and p=0.05 respectively). Conclusions: In this study, geriatric conditions which are usually unrecognized in a regular oncology office visit were identified. Our study indicates TUG and ADL might be use as predictive tests for hospitalization in elderly oncology populations. Also thrombocytopenia, and vitamin B12 and folic acid deficiencies are among the risk factors for hospitalization. The importance of vitamin B12 and folic acid vitamin replacement should not be underestimated in this population.
- Published
- 2015
11. Expectations of response from octreotide therapy in recurrent phosphaturic mesenchymal tumors--do they reflect reality?
- Author
-
Arife Ulas, Mehmet Ali Nahit Sendur, Didem Sener Dede, Muhammed Bulent Akinci, and Bulent Yalcin
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,Epidemiology ,business.industry ,Mesenchymal stem cell ,Public Health, Environmental and Occupational Health ,MEDLINE ,Octreotide ,medicine.disease ,Prognosis ,Surgery ,Neoplasm Recurrence ,Internal medicine ,medicine ,Humans ,Mesenchymoma ,Neoplasm Recurrence, Local ,business ,Hypophosphatemia ,Hypophosphatemia, Familial ,medicine.drug - Published
- 2015
12. Neutrophil to lymphocyte ratio--not an independent prognostic factor in patients with the myelodysplastic syndrome
- Author
-
Sema Akinci, Arife Ulas, Tuba Hacibekiroglu, Kamile Silay, Muhammed Bulent Akinci, Afra Alkan, Abdulkadir Basturk, Imdat Dilek, and Tekin Guney
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Prognostic factor ,Epidemiology ,Neutrophils ,Gastroenterology ,Risk Factors ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,In patient ,Lymphocytes ,Neutrophil to lymphocyte ratio ,Survival rate ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Cytopenia ,business.industry ,Mortality rate ,fungi ,Confounding ,Public Health, Environmental and Occupational Health ,Middle Aged ,medicine.disease ,Prognosis ,Pancytopenia ,Survival Rate ,Oncology ,Myelodysplastic Syndromes ,Immunology ,Female ,business ,Follow-Up Studies - Abstract
Purpose Neutrophil-to-lymphocyte ratio (NLR) was evaluated as a potential prognostic factor in patients with myelodysplastic syndrome (MDS). Materials and methods Between December 2009 and April 2014, 14 female (35%) and 26 male (65%) MDS patients who were followed up in our hematology clinic were included in the study for NLR during diagnosis. Division was into two groups according to the NLR, and the correlation with mortality was evaluated. The prognostic significance of NLR regarding treatment outcome was also evaluated with adjustment for known confounding risk factors. Results The mortality rate of the patient group was 55%, and median survival was 18 months. There was no significant correlation between mortality and NLR at a median value of 1.8 (p=0.75). Thrombocytopenia was observed to increase mortality (p=0.027), and there was a significant correlation between mortality and pancytopenia (p=0.017). Conclusions This first study of NLR and mortality did not show any significant correlation . In centres with limited access to genetic evaluation for the presence of pancytopenia and/or thrombocytopenia at the time of diagnosis, a platelet level less than 50?109/l may be poor prognostic markers in MDS patients.
- Published
- 2015
13. Substance P is a major mediator causing delayed emesis in anthracycline-based chemotherapy--really?
- Author
-
Arife Ulas, Kamile Silay, Sema Akinci, and Bulent Yalcin
- Subjects
Male ,Cancer Research ,Chemotherapy ,Anthracycline ,Epidemiology ,business.industry ,Vomiting ,medicine.medical_treatment ,Morpholines ,Public Health, Environmental and Occupational Health ,Substance P ,Breast Neoplasms ,Pharmacology ,Dexamethasone ,chemistry.chemical_compound ,Mediator ,Oncology ,chemistry ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Female ,business - Published
- 2015
14. Medication errors in chemotherapy preparation and administration: A survey conducted among oncology nurses in Turkey
- Author
-
Bulent Yalcin, Arife Ulas, Erdem Cubukcu, Didem Sener Dede, Sema Akinci, Abdurrahman Isikdogan, Nilufer Avci, Mehmet Ali Nahit Sendur, Abdullah Büyükçelik, Ahmet Bilici, Mevlude Inanc, Mustafa Degirmenci, Hasan Şenol Coşkun, Sener Cihan, Hatice Odabasi, Nuriye Ozdemir, Muhammed Bulent Akinci, Güngör Utkan, and Kamile Silay
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Turkey ,Epidemiology ,medicine.medical_treatment ,MEDLINE ,Nurses ,Antineoplastic Agents ,Nursing ,Nursing Staff, Hospital ,Drug Administration Schedule ,symbols.namesake ,Young Adult ,Internal medicine ,Neoplasms ,Surveys and Questionnaires ,medicine ,Humans ,Chemotherapy ,Medication Errors ,Medical prescription ,Young adult ,Intensive care medicine ,Fisher's exact test ,Descriptive statistics ,business.industry ,Public Health, Environmental and Occupational Health ,Workload ,Middle Aged ,Pharmaceutical Preparations ,Chemotherapeutic Drug Preparation/Administration ,symbols ,business ,Administration (government) - Abstract
Background: Medication errors in oncology may cause severe clinical problems due to low therapeutic indices and high toxicity of chemotherapeutic agents. We aimed to investigate unintentional medication errors and underlying factors during chemotherapy preparation and administration based on a systematic survey conducted to reflect oncology nurses experience. Materials and Methods: This study was conducted in 18 adult chemotherapy units with volunteer participation of 206 nurses. A survey developed by primary investigators and medication errors (MAEs) defined preventable errors during prescription of medication, ordering, preparation or administration. The survey consisted of 4 parts: demographic features of nurses; workload of chemotherapy units; errors and their estimated monthly number during chemotherapy preparation and administration; and evaluation of the possible factors responsible from ME. The survey was conducted by face to face interview and data analyses were performed with descriptive statistics. Chi-square or Fisher exact tests were used for a comparative analysis of categorical data. Results: Some 83.4% of the 210 nurses reported one or more than one error during chemotherapy preparation and administration. Prescribing or ordering wrong doses by physicians (65.7%) and noncompliance with administration sequences during chemotherapy administration (50.5%) were the most common errors. The most common estimated average monthly error was not following the administration sequence of the chemotherapeutic agents (4.1 times/month, range 1-20). The most important underlying reasons for medication errors were heavy workload (49.7%) and insufficient number of staff (36.5%). Conclusions: Our findings suggest that the probability of medication error is very high during chemotherapy preparation and administration, the most common involving prescribing and ordering errors. Further studies must address the strategies to minimize medication error in chemotherapy receiving patients, determine sufficient protective measures and establishing multistep control mechanisms.
- Published
- 2015
15. The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)
- Author
-
Kamile Silay, Arife Ulas, F.B. Asan, Burak Bilgin, Bulent Yalcin, S. Ayik, D. Sener Dede, Muhammed Bulent Akinci, Mehmet Ali Nahit Sendur, B. Gumuskaya Ocal, Mutlu Hizal, and H. Tatli Dogan
- Subjects
Mutation ,Programmed cell death ,biology ,business.industry ,Tumor-infiltrating lymphocytes ,Hematology ,medicine.disease_cause ,Ligand (biochemistry) ,Molecular biology ,Isocitrate dehydrogenase ,Oncology ,PD-L1 ,biology.protein ,Cancer research ,Medicine ,business ,Programmed death - Published
- 2017
16. The association and prognostic significance of programmed death-ligand 1 (PD-L1) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM) patients
- Author
-
Bulent Yalcin, Didem Sener Dede, Kamile Silay, Burak Bilgin, Fatma Betul Asan, Mehmet Ali Nahit Sendur, Hayriye Tatlı Doğan, Sule Ayik, Berrak Gumuskaya, Mutlu Hizal, Arife Ulas, and Bulent Akinci
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Mutation ,biology ,business.industry ,Newly diagnosed ,Ligand (biochemistry) ,medicine.disease_cause ,Isocitrate dehydrogenase ,Oncology ,PD-L1 ,biology.protein ,medicine ,Cancer research ,business ,Programmed death - Abstract
e13536 Background: We aimed to assessed thePD-L1, PD-1 expression, TILs and IDH-1 mutation associations and their prognostic importance in GBM. Methods: Newly diagnosed and all were operated GBM patients who folllowed between February 2006 to February 2017 were included retrospectively in the study. We assessed the PD-L1, PD-1 expression, CD4(+) ve CD8(+)TILs, IDH-1 mutation in initial tumor specimens. Immunohistochemistry was performed using Ventana® antibody (clon-SP263, ROCHE) for PD-L1 and PD-1, real time PCR used for IDH-1 mutation analysis. Intensity was graded as low, moderate, dense for PD-1, CD4, CD8 TILs. PD-L1 evaluated in percents. The cutoff value assumed as ≥5% for PD-L1 positivity. We used Kaplan Meier, Cox regression tests and SPSS 23. Results: Fourty eight patients included in the study. The mean age was 54± 14,4 and 34 (70%) patients were male. Thirty (70 %) patients were received chemoradiotherapy with temozolamide and 20 (41%) of them also received chemotherapy.We identified two different staining pattern of PD-L1 expression as diffuse fibrillary [13(27%)] and membranous staining [14(29%)]. IDH-1 mutation was found in 30 (62%) patients. We found that TILs were more intensely located in the perivascular area than intratumoral area and in that TILs, PD-1 intensity were dense. We also found a correlation between the percentages of PD-L1 positivity and the density of TILs in the intratumoral and perivascular areas (p < 0,002, r = 0,46). The intensity of both TILs in perivascular areas were significantly lower in PD-L1 (-) tumors than in PD-L1 (+) tumors (p < 0,001). We didn’t find any association between IDH-1 and PD-L1 or TILs. According to survival and multivariate analysis; age, sex, PD-L1 positivity and IDH-1 mutation status did not appear to have a significant effect on survival. (log rank 0,08; 0,30; 0,89; 0,14 respectively) The presence of dense intratumoral CD8(+) and PD-1 (+)TILs were found as positive; advanced age and membranous PD-L1 staining was found as negative independent prognostic factors. Conclusions: Different staining pattern of PD-L1 in tumor tissue and PD-1 positivity in TILs may be a prognostic importance in GBM
- Published
- 2017
17. Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature
- Author
-
Arife Ulas, Muhammed Bulent Akinci, Kamile Silay, Yunus Halil Polat, Mehmet Ali Nahit Sendur, Bulent Yalcin, Didem Sener Dede, and Sema Akinci
- Subjects
Cisplatin ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,Thrombotic microangiopathy ,Ifosfamide ,business.industry ,medicine.medical_treatment ,Thrombotic thrombocytopenic purpura ,Articles ,medicine.disease ,Chemotherapy regimen ,Gastroenterology ,Surgery ,Regimen ,Oncology ,Internal medicine ,hemic and lymphatic diseases ,Medicine ,Plasmapheresis ,business ,medicine.drug - Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare form of thrombotic microangiopathy that is characterized by microvascular thrombosis, thrombocytopenia, hemolysis and end organ damage. An extensive variety of drugs, including certain chemotherapeutic agents, have been associated with TTP. However, paclitaxel, cisplatin and ifosfamide regimen (TIP)-induced TTP has not previously been described. The present study reports the case of a 43-year-old patient with a refractory testicular germ cell tumor who developed acute TTP during TIP chemotherapy. Following the third cycle of TIP chemotherapy, the patient developed fever, anemia, thrombocytopenia and confusion. A diagnosis of TTP was established. Plasmapheresis was initiated as daily treatment in the first week, then continued every other day for 4 weeks. TIP chemotherapy was discontinued. The patient's clinical and neurological symptoms improved markedly after a week. Renal function and hemolysis improved, and the patient was discharged in a stable condition. The patient did not develop any complications and has been in remission for 5 months. The Naranjo adverse drug reaction probability scale indicated a likely association between TTP and the TIP chemotherapy regimen in this patient. This case is also investigated with regard to the associated literature to increase the awareness of TTP following chemotherapy.
- Published
- 2014
18. Treatment and prognosis in mucosal. melanoma: An Anatolian Society of Medical Oncology Study
- Author
-
Oktay Bozkurt, Mukremin Uysal, Ibrahim Vedat Bayoglu, Ahmet Alacacioglu, Melike Ozcelik, Turkan Ozturk Topcu, Nuriye Ozdemir, Ozlem Ercelep, Alper Sevinc, Sebnem Yaman, Ahmet Siyar Ekinci, Ozge Gumuscay, Berna Oksuzoglu, Arife Ulas, Mahmut Gumus, Asude Aksoy, Sernaz Uzunoglu, and Burcu Yapar Taskoylu
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Clinical course ,Mucosal melanoma ,medicine.disease ,Internal medicine ,Cutaneous melanoma ,Medicine ,business ,neoplasms ,Rare disease - Abstract
e20051 Background: Mucosal melanoma is a rare disease that is clearly distinct from cutaneous melanoma in clinical course and prognosis. We aim to evaluate patients with mucosal melanoma of differe...
- Published
- 2014
19. Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue
- Author
-
Gamze Gokoz Dogu, Omer Kamil Yazici, Mevlude Inanc, Ozgur Tanriverdi, Oznur Bal, Alper Sevinc, Ibrahim Turker, Arife Ulas, Yusuf Gunaydin, Tulay Akman, Özlem Sönmez, Ayşe Demirci, Ayse Durnali, Melike Ozcelik, Necati Alkis, Dogan Yazilitas, Umut Demirci, Saadet Tokluoglu, Muhammet Ali Kaplan, and Faysal Dane
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Estrogen receptor ,Cancer ,medicine.disease ,Breast cancer ,medicine.anatomical_structure ,Hormone receptor ,Internal medicine ,Invasive lobular carcinoma ,Progesterone receptor ,Medicine ,business ,Lymph node ,Gonadotropin-releasing hormone analogue - Abstract
e11542 Background: Breast cancer is the most common cancer in women. Approximately 60% of breast cancer are hormone receptor positive. The goal of this study is to evaluate the possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH). Methods: Demographic characteristics, treatment modalities, overall survival and the possible factors affecting the survival a total of 539 premenoposal breast cancer patients from 16 different centers in Turkey analysed retrospectively. Results: Median age was 36±6.3 (19-53). The median tumour size was 2.5±1.8 (0.5-13) cm. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) positivity rates were 92.0%, 90.4% 31.4% respectively. Histology of the tumors were as follows; invasive ductal carcinoma in 85.3%, invasive lobular carcinoma in 4.6%, mixed in 4.6%, and other subtypes in 5.3%. T staging were T1, T2, T3, T4 in 25.8%, 49.9%, 13.4%, 1,7% respectively. Lymph node involvement was in...
- Published
- 2014
20. Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology
- Author
-
Ummugul Uyeturk, Zuhat Urakci, Ulku Yalcintas Arslan, Berna Oksuzoglu, Veli Berk, Cemil Bilir, Oznur Bal, Didem Tastekin, Ibrahim Turker, Arife Ulas, Özlem Sönmez, Dogan Yazilitas, Sener Cihan, Mukremin Uysal, Nur Sener, Burcin Budakoglu, Ugur Yilmaz, Tulay Akman, and Zonguldak Bülent Ecevit Üniversitesi
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Turkey ,Survival ,Receptor, ErbB-2 ,medicine.medical_treatment ,Antineoplastic Agents ,Breast Neoplasms ,Antibodies, Monoclonal, Humanized ,Metastasis ,Young Adult ,Trastuzumab ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Neoplasm Metastasis ,Stage (cooking) ,Operation ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,Hematology ,business.industry ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Primary tumor ,Metastatic breast cancer ,Hormones ,Treatment ,Radiation therapy ,Treatment Outcome ,Multivariate Analysis ,Primary metastatic breast carcinoma ,Female ,business ,medicine.drug - Abstract
Primary metastatic breast cancer (PMBC) comprises 3-10 % of all BCs. PMBC is a heterogeneous disease. To date, little is known about the tumor characteristics, treatment results, and overall survival (OS) of patients with PMBC. Patients were considered to have PMBC if distant metastasis was evident within 3 months of the initial diagnosis of BC. Between September 2007 and April 2013, 466 PMBC patients were included in this study and analyzed retrospectively. The median age of the patients was 50 (18-90) years. Bone/soft tissue metastases were more frequent in the hormone receptor (HR)(+) human epidermal growth factor receptor (HER)2(-) group compared with the HR(-)HER2(-) and HR(-)HER2(+) groups (p < 0.001), whereas visceral organ metastasis was more frequent in the HR(-)HER2(-) and HR(-)HER2(+) groups (p < 0.001). The OS was affected by Eastern Cooperative Oncology Group performance status, tumor histology, receptor status, and the site of metastasis (p < 0.001, p < 0.001, p < 0.001, and p = 0.011, respectively). According to the first-line systemic treatment choices of the patients, the longest median OS was observed in the HR(+)HER2(+) group who received hormonotherapy combined with trastuzumab after chemotherapy (86 months, 95 % CI 23.8-148.1) and the shortest median OS was observed in the HR(-)HER2(-) group who received chemotherapy only (24 months, 95 % CI 17.9-30.0) (p < 0.001). Bisphosphonate therapy or radiotherapy had no significant effect on OS (p = 0.733, 0.603). In multivariate analysis, hormonotherapy, chemotherapy + trastuzumab, trastuzumab + hormonotherapy following chemotherapy, and surgery were the most important prognostic factors for OS, respectively (p < 0.001, p = 0.025, p = 0.027, p = 0.029). The general characteristics of the primary tumor are important for the prognosis and survival of patients with PMBC. Interestingly, patients who underwent primary breast tumor surgery, even those at the metastatic stage upon admission, had the longest survival. © 2014 Springer Science+Business Media New York.
- Published
- 2014
21. Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology
- Author
-
Oznur Bal, Arife Ulas, Necati Alkis, Mevlude Inanc, Ahmet Bilici, Alper Sevinc, Lokman Koral, Gulnihal Tufan, Tugba Yavuzsen, Nalan Akgul Babacan, Metin Ozkan, Mesut Seker, Ali Inal, Emin Tamer Elkiran, Tulay Akman, Bala Basak Oven Ustaalioglu, Mahmut Gumus, ŞEKER, MESUT, and Selçuk Üniversitesi
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Epidemiology ,Carcinoid tumors ,Sex Cord-Gonadal Stromal Tumors ,Ovary ,Internal medicine ,medicine ,Humans ,Progression-free survival ,Stage (cooking) ,Rare Ovarian Tumors ,Survival rate ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Ovarian Neoplasms ,Univariate analysis ,business.industry ,Overall Survival ,Prognostic Factors ,Public Health, Environmental and Occupational Health ,Retrospective cohort study ,Middle Aged ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Prognosis ,Progression-Free Survival ,Survival Rate ,medicine.anatomical_structure ,Female ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
WOS: 000329829200052, PubMed: 24377556, Background: Non-epithelial malignant ovarian tumors and clear cell carcinomas, Brenner tumors, transitional cell tumors, and carcinoid tumors of the ovary are rare ovarian tumors (ROTs). In this study, our aim was to determine the clinicopathological features of ROT patients and prognostic factors associated with survival. Materials and Methods: A total of 167 patients with ROT who underwent initial surgery were retrospectively analyzed. Prognostic factors that may influence the survival of patients were evaluated by univariate and multivariate analyses. Results: Of 167 patients, 75 (44.9%) were diagnosed with germ-cell tumors (GCT) and 68 (40.7%) with sex cord-stromal tumors (SCST); the remaining 24 had other rare ovarian histologies. Significant differences were found between ROT groups with respect to age at diagnosis, tumor localization, initial surgery type, tumor size, tumor grade, and FIGO stage. Three-year progression-free survival (PFS) rates and median PFS intervals for patients with other ROT were worse than those of patients with GCT and SCST (41.8% vs 79.6% vs 77.1% and 30.2 vs 72 vs 150 months, respectively; p=0.01). Moreover, the 3-year overall survival (OS) rates and median OS times for patients with both GCT and SCST were better as compared to patients with other ROT, but these differences were not statistically significant (87.7% vs 88.8% vs 73.9% and 170 vs 122 vs 91 months, respectively; p=0.20). In the univariate analysis, tumor localization (p
- Published
- 2014
22. Bone Metastasis From Gastric Cancer: The Incidence, Clinicopathological Features, And Influence On Survival
- Author
-
Fatma Paksoy Turkoz, Mustafa Solak, Arife Ulas, Suayib Yalcin, Saadettin Kilickap, Onur Esbah, Berna Oksuzoglu, and İç Hastalıkları
- Subjects
Cancer Research ,medicine.medical_specialty ,Pathology ,Survival ,medicine.medical_treatment ,Stomach neoplasms ,Gastroenterology ,Carcinoembryonic antigen ,Internal medicine ,medicine ,Zoledronic acid ,Chemotherapy ,Performance status ,biology ,business.industry ,Hazard ratio ,Bone metastasis ,Cancer ,Prognosis ,medicine.disease ,Oncology ,biology.protein ,Adenocarcinoma ,Original Article ,business ,medicine.drug - Abstract
Purpose To evaluate the incidence, clinicopathological characteristics, treatment outcomes, prognostic factors, and survival of gastric cancer patients with bone metastases. Materials and Methods Of 4,617 gastric cancer patients who were treated between 2001 and 2013, 176 patients with bone metastases were analyzed. Results The incidence of bone metastasis was 3.8%. The most common histopathological subtype was adenocarcinoma (79%) with poor differentiation (60.8%). The median interval from the diagnosis to bone metastasis was 11 months. The median survival time after bone metastasis was 5.4 months. Factors that were associated with longer median survival times included the following: isolated bone metastasis (P=0.004), well-differentiated tumors (P=0.002), palliative chemotherapy (P=0.003), zoledronic acid treatment (P
- Published
- 2014
23. Docetaxel and Cisplatin in First Line Treatment of Patients with Unknown Primary Cancer: A Multicenter Study of the Anatolian Society of Medical Oncology
- Author
-
Metin Ozkan, Halit Karaca, Nuriye Ozdemir, Ugur Coskun, Arife Ulas, Meltem Baykara, Mustafa Benekli, Suleyman Buyukberber, Faysal Dane, and Umut Demirci
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Epidemiology ,Antineoplastic Agents ,Docetaxel ,Neutropenia ,Mucoepidermoid carcinoma ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Carcinoma ,Humans ,Progression-free survival ,Neoplasm Metastasis ,Aged ,Retrospective Studies ,business.industry ,Public Health, Environmental and Occupational Health ,Middle Aged ,medicine.disease ,Regimen ,Treatment Outcome ,Adenocarcinoma ,Neoplasms, Unknown Primary ,Female ,Taxoids ,Cisplatin ,business ,Febrile neutropenia ,medicine.drug - Abstract
Background: The overall prognosis for cancers of unknown primary (CUP) is poor, median overall survival (OS) being 6-12 months. We evaluated our multicentric retrospective experience for CUP administered docetaxel and cisplatin combination therapy. Materials and Methods: A total of 29 patients that were pathologically confirmed subtypes of CUP were included in the study. The combination of docetaxel (75 mg/m 2 , day 1) and cisplatin (75 mg/m 2 , day 1) was performed as a first line regimen every 21 days. Results: The median age was 51 (range: 27-68). Some 17 patients had multimetastatic disease on the inital diagnosis. Histopathological diagnoses were well-moderate differentiated adenocarcinoma (51.7%), undifferentiated carcinoma (27.6%), squamous cell cancer (13.8%), mucoepidermoid carcinoma (3.4%) and neuroendocrine differentiated carcinoma (3.4%). Median number of cycles was 3 (range: 1-6). Objective response rate was 37.9% and clinical benefit was 58.6%. Median progression free survival (PFS) and overall survival (OS) were 6 months (range: 4.3-7.7 months) and 16 months (range: 8.1-30.9 months), respectively. Fourteen patients (60.8%) were treated in a second line setting. There was no treatment related death. Most common toxicities were nausia-vomiting (44.6%) and fatigue (34.7%), serious cases (grade 3/4) suffering nausia-vomiting (10.3%), neutropenia (13.8%) and febrile neutropenia (n=1). Conclusion: The combination of cisplatin and docetaxel is an effective regimen for selected patients with CUP.
- Published
- 2014
24. Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab
- Author
-
Halit Karaca, Nur Sener, Yildirim Ozdemir N, Mustafa Benekli, Suleyman Buyukberber, Arife Ulas, Yusuf Gunaydin, Coskun U, Ramazan Yildiz, Onder Tonyali, Tulay Akman, Umit Unal O, Mahmut Gumus, Mehmet Kucukoner, Umut Demirci, Mevlude Inanc, Dogan Yazilitas, and Oznur Bal
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Turkey ,genetic structures ,Receptor, ErbB-2 ,medicine.medical_treatment ,Antineoplastic Agents ,Breast Neoplasms ,Antibodies, Monoclonal, Humanized ,Disease-Free Survival ,Young Adult ,Text mining ,Breast cancer ,Risk Factors ,Trastuzumab ,Internal medicine ,Recurrence free survival ,Prevalence ,medicine ,Humans ,In patient ,Stage (cooking) ,skin and connective tissue diseases ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Incidence ,Early disease ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,Treatment Outcome ,Female ,Neoplasm Recurrence, Local ,business ,Adjuvant ,medicine.drug - Abstract
Background: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC). Patients and Methods: The medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC. Survival was estimated using the Kaplan-Meier method. Univariate analyses of RFS were performed with the log-rank test. Independent prognostic and predictive factors affecting RFS were assessed by Cox regression analysis. Results: Median follow-up time was 33.1 months (range 9.2-75.9 months). 3-year RFS and overall survival were 87 and 97%, respectively. In multivariate analysis, patients aged 70 years or over (p = 0.017, relative risk (RR) 2.7, 95% confidence interval (CI) 1.19-6.13), patients with > 9 positive lymph nodes (p = 0.001, RR 2.52, 95% CI 1.42-4.46), and those with progesterone receptor-negative tumors (p = 0.006, RR 2.33, 95% CI 1.27-4.27) had worse RFS. Conclusion: In spite of a 52-week adjuvant trastuzumab treatment, classic poor prognostic factors for invasive EBC remained as such in patients with HER2-positive EBC.
- Published
- 2013
25. Prognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiences
- Author
-
Oznur Bal, Arife Ulas, Tulay Eren, Ali Inal, Olcun Umit Unal, Ahmet Bilici, Serap Kaya, Mustafa Benekli, Mahmut Gumus, Suleyman Alici, Veli Berk, Bala Basak Oven Ustaalioglu, Umut Demirci, and Nedim Turan
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Adjuvant Chemotherapy ,Epidemiology ,medicine.medical_treatment ,Disease-Free Survival ,Pneumonectomy ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Carcinoma ,medicine ,Humans ,Lymph Node Negative ,Stage (cooking) ,Lung cancer ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Hazard ratio ,Public Health, Environmental and Occupational Health ,Middle Aged ,Prognosis ,medicine.disease ,Non-Small Cell Lung Cancer ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,Mediastinal lymph node ,Lymph Node Excision ,T-stage ,Female ,Lymph Nodes ,Neoplasm Recurrence, Local ,business ,Wedge resection (lung) - Abstract
Background: Surgery is the only curative treatment for operable non-small lung cancer (NSCLC) and the importance of adjuvant chemotherapy for stage IB patients is unclear. Herein, we evaluated prognostic factors for survival and factors related with adjuvant treatment decisions for stage I and IIA NSCLC patients without lymph node metastasis. Materials and Methods: We retrospectively analyzed 302 patients who had undergone curative surgery for prognostic factors regarding survival and clinicopathological factors related to adjuvant chemotherapy. Results: Nearly 90% of the patients underwent lobectomy or pneumonectomy with mediastinal lymph node resection. For the others, wedge resection were performed. The patients were diagnosed as stage IA in 35%, IB in 49% and IIA in 17%. Histopathological type (p=0.02), tumor diameter (p=0.01) and stage (p
- Published
- 2013
26. Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience
- Author
-
Mustafa Benekli, Cem Boruban, Mehmet Ali Kaplan, Ibrahim Turker, Arife Ulas, Hakan Harputluoglu, Lokman Koral, Burcak Yilmaz, Berna Oksuzoglu, Dogan Koca, Dogan Uncu, Abdurrahman Isikdogan, Bulent Cetin, Faysal Dane, Alper Sevinc, Suleyman Buyukberber, Ugur Coskun, Veli Berk, Cetin, Bulent, Benekli, Mustafa, Oksuzoglu, Berna, Koral, Lokman, Ulas, Arife, Dane, Faysal, Turker, Ibrahim, Kaplan, Mehmet A., Koca, Dogan, Boruban, Cem, Yilmaz, Burcak, Sevinc, Alper, Berk, Veli, Isikdogan, Abdurrahman, Uncu, Dogan, Harputluoglu, Hakan, Coskun, Ugur, and Buyukberber, Suleyman
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Combination therapy ,Turkey ,Receptor, ErbB-2 ,medicine.medical_treatment ,TRASTUZUMAB ,Breast Neoplasms ,Lapatinib ,GW572016 ,Deoxycytidine ,Capecitabine ,Internal medicine ,HER2 ,Antineoplastic Combined Chemotherapy Protocols ,Prevalence ,Medicine ,Humans ,skin and connective tissue diseases ,Survival rate ,Aged ,Retrospective Studies ,Chemotherapy ,business.industry ,TEMOZOLOMIDE ,Brain metastases ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Metastatic breast cancer ,Rash ,Survival Analysis ,Survival Rate ,Treatment Outcome ,Quinazolines ,Female ,Fluorouracil ,medicine.symptom ,business ,PHASE-II TRIAL ,Progressive disease ,medicine.drug - Abstract
Background: We investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) treated with lapatinib and capecitabine (LC). Patients and Methods: A total of 203 patients with HER2+ MBC, who had progressed after trastuzumab-containing chemotherapy, were retrospectively evaluated in 11 centers between September 2009 and May 2011. 85 patients who had developed BMs before the initiation of treatment with LC were included. All patients had received prior cranial radiotherapy. All patients were treated with the combination of lapatinib (1,250 mg/day continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Results: The median follow-up was 10.5 months (range 1-38 months). An overall response rate of 27.1% was achieved, including complete response in 2 (2.4%) and partial response in 21 (24.7%) patients. Median progression-free survival was 7 months (95% confidence interval (CI) 5-9), with a median overall survival of 13 months (95% Cl 9-17). The most common side effects were hand-foot syndrome (58.8%), nausea (55.3%), fatigue (48.9%), anorexia (45.9%), rash (36.5%), and diarrhea (35.4%). Grade 3-4 toxicities were hand-foot syndrome (9.4%), diarrhea (8.3%), fatigue (5.9%), and rash (4.7%). There were no symptomatic cardiac events. Conclusion: LC combination therapy was effective and well-tolerated in patients with HER2+ MBC with BMs, who had progressive disease after trastuzumab-containing therapy., BACKGROUND: We investigated the clinical outcome of patients with brainmetastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+)metastatic breast cancer (MBC) treated with lapatinib and capecitabine (LC).PATIENTS AND METHODS: A total of 203 patients with HER2+ MBC, who had progressed after trastuzumab-containing chemotherapy, were retrospectively evaluated in 11centers between September 2009 and May 2011. 85 patients who had developed BMsbefore the initiation of treatment with LC were included. All patients hadreceived prior cranial radiotherapy. All patients were treated with thecombination of lapatinib (1,250 mg/day continuously) and capecitabine (2,000mg/m(2) on days 1-14 of a 21-day cycle).RESULTS: The median follow-up was 10.5 months (range 1-38 months). An overallresponse rate of 27.1% was achieved, including complete response in 2 (2.4%) and partial response in 21 (24.7%) patients. Median progression-free survival was 7months (95% confidence interval (CI) 5-9), with a median overall survival of 13months (95% Cl 9-17). The most common side effects were hand-foot syndrome(58.8%), nausea (55.3%), fatigue (48.9%), anorexia (45.9%), rash (36.5%), anddiarrhea (35.4%). Grade 3-4 toxicities were hand-foot syndrome (9.4%), diarrhea(8.3%), fatigue (5.9%), and rash (4.7%). There were no symptomatic cardiacevents.CONCLUSION: LC combination therapy was effective and well-tolerated in patientswith HER2+ MBC with BMs, who had progressive disease after trastuzumab-containingtherapy.
- Published
- 2012
27. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer
- Author
-
Arife Ulas, Suleyman Buyukberber, Veli Berk, Nuriye Ozdemir, Ilhan Oztop, Ozan Balakan, Mehmet Kucukoner, Aytug Uner, Faysal Dane, Dogan Koca, Ugur Yilmaz, Nedim Turan, Basak Oven Ustaalioglu, Mehmet Akif Ozturk, Mahmut Gumus, Kaan Helvaci, Mustafa Benekli, and Seçil Özkan
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,Colorectal cancer ,Adjuvant chemotherapy ,medicine.medical_treatment ,Angiogenesis Inhibitors ,Antibodies, Monoclonal, Humanized ,Systemic therapy ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,Neoplasm Metastasis ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Systemic chemotherapy ,Liver Neoplasms ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Chemotherapy combinations ,Survival Rate ,Chemotherapy, Adjuvant ,Female ,Neoplasm Recurrence, Local ,business ,Colorectal Neoplasms ,Adjuvant ,medicine.drug ,Follow-Up Studies - Abstract
Background: We aimed to investigate the impact of adjuvant systemic therapy with modern chemotherapy combinations on survival outcomes in patients with resected liver-confined metastases from colorectal carcinomas, and whether addition of bevacizumab (BEV) provides further benefit. Methods: A total of 229 consecutive patients who underwent resection for liver-confined colorectal liver metastases were retrospectively analyzed. Results: Of 229 patients, 204 who received chemotherapy with fluoropyrimidine-based (n = 27), irinotecan-based (n = 84) and oxaliplatin-based (n = 93) combinations were analyzed. Among these, 87 patients received BEV while 117 did not (NoBEV). With a median follow-up of 27 months after metastasectomy, the median recurrence-free survival (RFS) and overall survival (OS) were 17 and 53 months, respectively. OS rates at 3 and 5 years were 71% and 40%, respectively. No significant differences were found in the median RFS (p = 0.744) and OS (p = 0.440) among different chemotherapy regimens. The median RFS (p = 0.375) and OS (p = 0.251) were similar in BEV and NoBEV arms. In multivariate analysis, having 4 liver metastases was the only negative independent factor on both RFS and OS, while positive surgical margin was another negative independent factor for RFS. Conclusion: Chemotherapy type and addition of BEV have no impact on both RFS and OS in the adjuvant setting following complete resection of colorectal liver metastases.
- Published
- 2012
28. Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology
- Author
-
Arife Ulas, Sebnem Yaman, Muhammed Ali Kaplan, Ozge Gumusay, Abdurrahman Isikdogan, Suleyman Buyukberber, Nuriye Ozdemir, Mehmet Kucukoner, Emir T Elkiran, Ali Inal, Zuhat Urakci, and Olcun Umit Unal
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Epidemiology ,Administration, Oral ,Salvage therapy ,Carcinoma, Ovarian Epithelial ,Medical Oncology ,Internal medicine ,medicine ,Carcinoma ,Humans ,Epithelial ovarian cancer ,Neoplasms, Glandular and Epithelial ,Survival rate ,Aged ,Etoposide ,Neoplasm Staging ,Platinum ,Retrospective Studies ,Aged, 80 and over ,Ovarian Neoplasms ,Salvage Therapy ,business.industry ,Public Health, Environmental and Occupational Health ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Survival Rate ,Toxicity ,Female ,Neoplasm Recurrence, Local ,Ovarian cancer ,Oral etoposide ,business - Abstract
Background: The aim of this study was to evaluate the efficacy and toxicity of long-term, low-dose oral etoposide as an advanced treatment option in patients with platinum resistant epithelial ovarian cancer. Materials and Methods: For the purposes of this study, 51 patients with histologically-confirmed, recurrent or metastatic platinum-resistant epithelial ovarian cancer (EOC) treated at six different centers between January 2006 and January 2011 were retrospectively evaluated. Patients were treated with oral etoposide (50 mg/day for a cycle of 14 days, repeated every 21 days). Results: Among the 51 platinum-resistant patients, 17.6% demonstrated a partial response and 25.5% a stable response. The median progression-free survival (PFS) was 3.9 months (95% CI, 2.1-5.7), while the median overall survival was 16.4 months (11.8–20.9). No significant relationship was observed between the pre-treatment CA 125 levels, post-treatment CA-125 levels and the treatment response rates (p=0.21). Among the 51 patients who were evaluated in terms of toxicity, grade 1 or 4 hematologic toxicity was observed in 19 (37.3%); and grade 1-4 gastrointestinal toxicity occurred in 15 patients (29.4%). Conclusions: Chronic low-dose oral etoposide treatment is generally effective and well-tolerated in platinum-resistant ovarian cancer patients.
- Published
- 2012
29. Primary gastric Hodgkin lymphoma and metachronous early gastric carcinoma: a case report
- Author
-
Arife Ulas, Necati Alkis, Ayse Durnali, Saadet Tokluoglu, and Fatma Paksoy Turkoz
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Dacarbazine ,medicine.medical_treatment ,Bleomycin ,Gastroenterology ,chemistry.chemical_compound ,immune system diseases ,Stomach Neoplasms ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,business.industry ,Stomach ,digestive, oral, and skin physiology ,Neoplasms, Second Primary ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Hodgkin Disease ,digestive system diseases ,Lymphoma ,Vinblastine ,medicine.anatomical_structure ,Oncology ,ABVD ,chemistry ,Adenocarcinoma ,Gastrectomy ,business ,medicine.drug - Abstract
Primary Gastric Hodgkin lymphoma is seen very rarely. Primary gastric Hodgkin lymphoma and gastric carcinoma in same patient is very very rare entity. Almost all of the primary gastric lymphoma cases are non-Hodgkin lymphoma type. We report the case of 45-year-old man with 3-month history of abdominal pain and weight loss. Upper gastrointestinal endoscopic examination revealed an ulcerated polypoid mass on greater curve of stomach and histopathological examination of biopsy showed adenocarcinoma. After near total gastrectomy, gastric Hodgkin lymphoma diagnosis was made, and postoperative 4 courses of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) regimen were administered, and then total 3,600 cGy radiotherapy was delivered. After 7 years, during control examination, early gastric carcinoma was diagnosed. Our case is very rare entity of gastric Hodgkin lymphoma and metachronous gastric carcinoma. This case also shows the importance of follow-up of patients not only for the relapse of primary disease but also for the development of secondary malignancy which can be diagnosed at early curable stage.
- Published
- 2010
30. Optimal timing of adjuvant treatment in patients with early breast cancer
- Author
-
Arife Ulas, Gokhan Celenkoglu, Sadık Muallaoğlu, Murat Koçer, Saadet Tokluoglu, Ulku Yalcintas Arslan, Ayse Durnali, Kadri Altundag, Güngör Utkan, Fatih Oğuz Önder, and Necati Alkis
- Subjects
Adult ,Selective Estrogen Receptor Modulators ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Antineoplastic Agents ,Breast Neoplasms ,Kaplan-Meier Estimate ,Disease-Free Survival ,Young Adult ,Breast cancer ,medicine ,Humans ,Young adult ,Mastectomy ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,Retrospective cohort study ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Tamoxifen ,Oncology ,Selective estrogen receptor modulator ,Chemotherapy, Adjuvant ,Female ,business ,Adjuvant ,medicine.drug - Abstract
It is well established that adjuvant treatment reduces mortality after early breast cancer. However, the optimal timing of adjuvant treatment is not well described. To determine the optimal timing of adjuvant treatment, 402 breast cancer patients who received adjuvant treatment at Ankara Oncology Research and Training Hospital between January 1995 and August 2002 were evaluated retrospectively. Three hundred and fifty-seven (88.8%) patients received adjuvant chemotherapy, 204 (50.7%) of these patients received only adjuvant chemotherapy and 153 (38%) patients received tamoxifen following chemotherapy. Remaining 45 (11.2%) patients received only adjuvant tamoxifen. The median time to start adjuvant treatment after surgery was day 21 (range, days 4 to days 258), and the median follow-up was 50 months (range, 6-105 months). The patients were divided into 5 groups according to starting time of chemotherapy (shorter than 14 days, between days 15-29, between days 30-44, between days 45.-59 and more than 59 days). Overall survival (OS) and disease-free survival (DFS) were not shown significantly different between for 5 groups (P>0.05). Secondly, patients were divided into two groups as starting adjuvant treatment equal to or shorter than 44 days and longer than 44 days (n=344, 85.6% and vs. n=58, 14.4%, respectively). OS was significantly better in patients who started to receive adjuvant treatment within 44 days after surgery compared to patients who received adjuvant treatment after 44 days (92 vs. 83.3%, P=0.03) for 5 years, but DFS was not significantly different between two groups (83.4 vs. 82.2%, P>0.05). According to our study, adjuvant treatment of breast cancer should be initiated earlier after surgery.
- Published
- 2010
31. Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial
- Author
-
Zeki Gokhan Surmeli, Isa Dede, Mert Basaran, Metin Kanitez, Muhammet Ali Kaplan, Nilufer Avci, Meltem Ekenel, Vedat Bayoglu, Tulay Akman, Mukremin Uysal, Umut Varol, Muharrem Kocar, Ozan Yazıcı, Arife Ulas, Deniz Tural, and Ibrahim Yildiz
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Sunitinib ,business.industry ,Turkish ,urologic and male genital diseases ,medicine.disease ,language.human_language ,Renal cell carcinoma ,Internal medicine ,medicine ,language ,In patient ,business ,Clear cell ,medicine.drug - Abstract
e15602 Background: Most of the randomizedstudies that have evaluated the clinical outcome of anti-VEGF treatment in metastatic renal cell carcinoma (RCC) were focused mostly on the clear cell histo...
- Published
- 2014
32. The impact of bevacizumab usage on patients who were curative resected for liver-confined metastases from colorectal cancer
- Author
-
Dogan Koca, Suleyman Buyukberber, Arife Ulas, Mahmut Gumus, Mehmet Akif Ozturk, Ugur Yilmaz, Ilhan Oztop, Mustafa Benekli, Faysal Dane, Seçil Özkan, Ozan Balakan, Mehmet Kucukoner, Nedim Turan, B. B. Oven Ustaalioglu, Nuriye Ozdemir, and Veli Berk
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,business.industry ,Colorectal cancer ,Internal medicine ,medicine ,Overall survival ,business ,medicine.disease ,medicine.drug - Abstract
e14120 Background: We investigate whether there have been differences in disease-free survival (DFS) and overall survival (OS) among patients who were treated with different cytotoxic regimens (flu...
- Published
- 2011
33. 5096 The discordance between hormonal receptor status and c-erb b2 in primary and metastatic breast cancer
- Author
-
F. Paksoy, Gokhan Celenkoglu, Burcin Budakoglu, Necati Alkis, U. Yalcintas Arslan, Saadet Tokluoglu, and Arife Ulas
- Subjects
Oncology ,CA15-3 ,Cancer Research ,medicine.medical_specialty ,Receptor Status ,business.industry ,C erb b2 ,Cancer ,medicine.disease ,Metastatic breast cancer ,Breast cancer ,Internal medicine ,Medicine ,business ,Hormone - Published
- 2009
34. 5108 Clinical outcomes and patients characteristics of triple negative breast carcinoma
- Author
-
U. Yalcintas Arslan, Arife Ulas, Dogan Uncu, Ibrahim Turker, Saadet Tokluoglu, Fatih Oğuz Önder, Ummugul Uyeturk, Gokhan Celenkoglu, and Necati Alkis
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Breast cancer ,business.industry ,Internal medicine ,medicine ,Patient characteristics ,Triple-Negative Breast Carcinoma ,medicine.disease ,business - Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.